keyword
MENU ▼
Read by QxMD icon Read
search

Recurrent ovarian

keyword
https://www.readbyqxmd.com/read/28319570/microcystic-elongated-and-fragmented-pattern-invasion-in-ovarian-endometrioid-carcinoma-immunohistochemical-profile-and-prognostic-implications
#1
Allison Goldberg, Lauren Hand, Dan DeCotiis, Norman Rosenblum, Joanna Chan
Microcystic, elongated, and fragmented (MELF) pattern invasion is a poor prognostic indicator in uterine endometrioid carcinoma, but its existence, biology, and prognostic value have not been described in ovarian endometrioid carcinoma. We evaluated cases of ovarian endometrioid carcinoma without synchronous uterine endometrioid carcinoma for MELF and other histologic features. To evaluate tumor biology, we assessed an immunohistochemical profile, including MLH1, PMS2, MSH2, MSH6, β-catenin, e-cadherin, CK19, and cyclin D1...
March 17, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28317584/dealing-with-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancer-a-surgical-challenge
#2
REVIEW
Henri Azaïs, Juan Pablo Estevez, Périne Foucher, Yohan Kerbage, Serge Mordon, Pierre Collinet
Understanding biology and progression mechanisms of peritoneal metastases of epithelial ovarian cancer (EOC) is a cornerstone in the knowledge and the comprehensive management of the disease. Despite clinical remission after the association of complete cytoreductive surgery and platinum-based chemotherapy, peritoneal recurrence still occurs in 60% of patients. Eligible studies, published from 1980 to June 2016, were retrieved through ClinicalTrials.gov, MEDLINE, Cochrane databases and bibliography searches...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28315410/is-lymphadenectomy-necessary-in-mucinous-ovarian-cancer-a-single-institution-experience
#3
Ivan Salgado Ceballos, Jazmín Ríos, Delia Pérez Montiel, Lenny Gallardo, Salim Barquet-Muñoz, Rosa Salcedo-Hernández, Carlos Pérez-Plasencia, Luis Alonso Herrera, David Francisco Cantú de León
BACKGROUND: According to the International Federation of Gynecology and Obstetrics (FIGO) guidelines, every patient diagnosed with ovarian cancer (OC) should undergo a complete staging procedure to adequately assess tumor spread. The role of lymphadenectomy in the initial management of primary early mucinous ovarian cancer (MOC) remains unclear. OBJECTIVE: To describe the prevalence of pelvic and para-aortic node metastases in MOC. MATERIALS AND METHODS: The records of patients with MOC treated at our Institute during January 2005 to December 2011 were assessed...
March 14, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28314990/an-apparent-clinical-pharmacokinetic-drug-drug-interaction-between-bevacizumab-and-the-anti-placental-growth-factor-monoclonal-antibody-ro5323441-via-a-target-trapping-mechanism
#4
Ka Wang, Franziska Schaedeli Stark, Tilman Schlothauer, Angelika Lahr, Valerie Cosson, Jianguo Zhi, Kai Habben, Jean Tessier, Eginhard Schick, Roland F Staack, Oliver Krieter
PURPOSE: RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an apparent drug-drug interaction observed when RO5323441 was administered in combination with bevacizumab. METHODS: The four Phase I studies were a multiple-ascending dose study in 23 patients with solid tumors (Study 1), an open-label study in seven patients with colorectal/ovarian cancer (Study 2), a sorafenib combination study in nine patients with hepatocellular carcinoma (Study 3), and a bevacizumab combination study in 22 patients with recurrent glioblastoma (Study 4)...
March 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28314588/risk-of-breast-cancer-after-a-diagnosis-of-ovarian-cancer-in-brca-mutation-carriers-is-preventive-mastectomy-warranted
#5
Jacob McGee, Vasily Giannakeas, Beth Karlan, Jan Lubinski, Jacek Gronwald, Barry Rosen, John McLaughlin, Harvey Risch, Ping Sun, William D Foulkes, Susan L Neuhausen, Joanne Kotsopoulos, Steven A Narod
OBJECTIVE: Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. METHODS: First, the annual mortality rate for ovarian cancer patients was estimated for a cohort of 178 BRCA mutation carriers from Ontario, Canada...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28314254/synchronous-endometrial-and-ovarian-cancer-in-young-women-case-report-and-review-of-the-literature
#6
REVIEW
Askin Dogan, Beate Schultheis, Günther A Rezniczek, Ziad Hilal, Cem Cetin, Günther Häusler, Clemens B Tempfer
BACKGROUND: Young women with endometrial cancer (EC) have an increased risk of synchronous ovarian cancer. The prognosis of women with synchronous endometrial and ovarian cancer (SEOC) is good. A high proportion of affected women have hereditary non-polyposis colon cancer syndrome (HNPCC). CASE PRESENTATION: We present the case of a 45-year-old woman with histologically proven endometrioid adenocarcinoma of the endometrium (pT1B, G2, R0 without lymphovascular space invasion)...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314183/identification-of-metabolic-biomarkers-using-serial-18-f-fdg-pet-ct-for-prediction-of-recurrence-in-advanced-epithelial-ovarian-cancer
#7
Tae Hun Kim, Junhwan Kim, Yeon-Koo Kang, Maria Lee, Hee Seung Kim, Gi Jeong Cheon, Hyun Hoon Chung
PURPOSE: To evaluate the prognostic value of metabolic parameters derived from serial (18)F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with advanced epithelial ovarian cancer (EOC). METHODS: Thirteen patients with advanced EOC who received surgical staging and adjuvant platinum-based combination chemotherapy were prospectively enrolled. (18)F-FDG PET/CT was performed before and after the surgical staging, and after third cycle of chemotherapy...
March 14, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28303528/human-mass-balance-study-and-metabolite-profiling-of-14-c-niraparib-a-novel-poly-adp-ribose-polymerase-parp-1-and-parp-2-inhibitor-in-patients-with-advanced-cancer
#8
Lotte van Andel, Z Zhang, S Lu, V Kansra, S Agarwal, L Hughes, M M Tibben, A Gebretensae, L Lucas, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen
Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive, ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy. Significant improvements in PFS were seen in all patient cohorts regardless of biomarker status...
March 16, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28299955/niraparib-for-the-treatment-of-ovarian-cancer
#9
Yada Kanjanapan, Stephanie Lheureux, Amit M Oza
Introduction Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are being developed in maintenance and recurrence treatment settings in ovarian cancer. They inhibit single-stranded DNA repair, inducing synthetic lethality in cells with underlying homologous recombination deficiency (HRD). Marked responses are seen in ovarian cancers with breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutation, although up to 50% of high-grade serous ovarian cancers (HGSOC) have HRD may also benefit. Areas covered This review focuses on niraparib (oral PARP I and II inhibitor), its clinical testing in ovarian cancer, including the Myriad MyChoice HRD test as a potential companion diagnostic...
March 16, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28293443/ovarian-mature-and-immature-teratomas-in-monozygotic-twins-a-case-report-of-simultaneous-presentation
#10
Daisuke Shigemi, Naoki Kawai, Toshiyuki Takeshita
Mature cystic teratoma is one of the most common kinds of ovarian tumor, and immature teratoma is a rare tumor, representing less than 1% of all ovarian teratomas. Although there are some reports about familial occurrences of ovarian tumors, literature concerning the clinical cases of monozygotic twins is rare. We report the 5-year clinical courses of a 12-year-old Japanese girl with a recurrent bilateral ovarian mature teratoma and her monozygotic twin with a unilateral ovarian mature teratoma and contralateral ovarian immature teratoma...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28291545/adding-bevacizumab-to-single-agent-chemotherapy-for-the-treatment-of-platinum-resistant-recurrent-ovarian-cancer-a-cost-effectiveness-analysis-of-the-aurelia-trial
#11
Weiya Z Wysham, Elisabeth M Schaffer, Theresa Coles, Dario R Roque, Stephanie B Wheeler, Kenneth H Kim
OBJECTIVE: AURELIA, a randomized phase III trial of adding bevacizumab (B) to single agent chemotherapy (CT) for the treatment of platinum-resistant recurrent ovarian cancer, demonstrated improved progression free survival (PFS) in the B+CT arm compared to CT alone. We aimed to evaluate the cost effectiveness of adding B to CT in the treatment of platinum-resistant recurrent ovarian cancer. METHODS: A decision tree model was constructed to evaluate the cost effectiveness of adding bevacizumab (B) to single agent chemotherapy (CT) based on the arms of the AURELIA trial...
March 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28288674/cytochrome%C3%A2-p450-oxidoreductase-deficiency-caused-by-r457h-mutation-in-por-gene-in-chinese-case-report-and-literature-review
#12
Yang Bai, Jinhui Li, Xiaoli Wang
BACKGROUND: Cytochrome P450 oxidoreductase deficiency (PORD) is a rare disease exhibiting a variety of clinical manifestations. It can be difficult to differentiate with other diseases such as 21-hydroxylase deficiency (21-OHD), polycystic ovary syndrome (PCOS) and Antley-Bixler syndrome (ABS). Nearly 100 cases of PORD have been reported worldwide. However, the genetic characters and clinical management are still unclear, especially in China. CASE PRESENTATION: In this study, we report a 27-year-old female Chinese patient who first presented with amenorrhea and recurrence of large ovary cyst...
March 14, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/28288660/evidence-of-metachronous-development-of-ovarian-teratomas-a-case-report-of-bilateral-mature-cystic-teratomas-of-the-ovaries-and-systematic-literature-review
#13
Wen-Chung Wang, Yen-Chein Lai
BACKGROUND: Mature cystic teratomas are usually found in the ovaries. They are bilateral in 10 to 15% of cases and multiple cystic teratomas may be present in one ovary. The aim of this study is to clarify if development of mature cystic teratomas of the ovaries in a single host is metachronous or due to autoimplant or recurrence. CASE PRESENTATION: We report a woman with bilateral mature cystic teratomas of the ovaries. DNA profiles of these teratomas were investigated via short tandem repeat (STR) analysis and methylation statuses were determined via methylation sensitive multiplex ligation-dependent probe amplification methods...
March 14, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/28288389/ovarian-ablation-for-premenopausal-breast-cancer-a-review-of-treatment-considerations-and-the-impact-of-premature-menopause
#14
REVIEW
Melica Nourmoussavi, Gary Pansegrau, Jason Popesku, Geoffrey L Hammond, Janice S Kwon, Mark S Carey
Historically, ovarian ablation (OA) was used as therapy for women with recurrent hormone-receptor-positive (HRP) premenopausal breast cancer. With the publication of the SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) randomized trials, there is considerable interest in OA as an adjuvant treatment, either in combination with tamoxifen or an aromatase inhibitor (AI). Thus, we have reviewed current guidelines and key studies on this important topic and have highlighted the relevant biological and pharmacological aspects of the various endocrine therapies...
February 22, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28286987/endometriosis-after-menopause-physiopathology-and-management-of-an-uncommon-condition
#15
I Streuli, H Gaitzsch, J-M Wenger, P Petignat
Endometriosis is a hormone-dependent inflammatory disease that is usually characterized by infertility and pain symptoms. This disease mainly occurs during the reproductive years and is rarely diagnosed after menopause. We discuss the physiopathology of this condition after menopause as well as treatment options and the risk of malignant transformation. Occurrence or progression of postmenopausal endometriosis lesions could be related to extra-ovarian production of estrogen by endometriosis lesions and adipose tissue, which becomes the major estrogen-producing tissue after menopause...
April 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28286660/preference-of-elderly-patients-to-oral-or-intravenous-chemotherapy-in-heavily-pre-treated-recurrent-ovarian-cancer-final-results-of-a-prospective-multicenter-trial
#16
Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter, Gülten Oskay-Oezcelik, Jalid Sehouli
BACKGROUND: Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints. METHODS: Patients with ROC had the free choice between treosulfan i...
2017: Gynecologic Oncology Research and Practice
https://www.readbyqxmd.com/read/28286604/a-review-of-mtor-pathway-inhibitors-in-gynecologic-cancer
#17
REVIEW
Andréia Cristina de Melo, Eduardo Paulino, Álvaro Henrique Ingles Garces
The treatment of advanced gynecologic cancers remains palliative in most of cases. Although systemic treatment has entered into the era of targeted drugs the antitumor efficacies of current therapies are still limited. In this context there is a great need for more active treatment and rationally designed targeted therapies. The PI3K/AKT/mTOR is a signaling pathway in mammal cells that coordinates important cell activities. It has a critical function in the survival, growth, and proliferation of malignant cells and was object of important research in the last two decades...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28285846/a-comparative-analysis-of-prediction-models-for-complete-gross-resection-in-secondary-cytoreductive-surgery-for-ovarian-cancer
#18
Renee A Cowan, Ane Gerda Zahl Eriksson, Sara M Jaber, Qin Zhou, Alexia Iasonos, Oliver Zivanovic, Mario M Leitao, Nadeem R Abu-Rustum, Dennis S Chi, Ginger J Gardner
OBJECTIVE: We sought to examine compliance and outcomes using Memorial Sloan Kettering "(MSK) criteria" to predict complete gross resection (CGR) and compare them with the validated Tian and AGO models. METHODS: Patients who underwent SCS for recurrent platinum-sensitive ovarian cancer from 5/2001-6/2014 were identified. The AGO and Tian models were applied to the study population; appropriate statistical tests were used to determine ability to predict CGR. RESULTS: 214 SCS cases were identified...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285055/the-role-of-routine-peritoneal-and-omental-biopsies-at-risk-reducing-salpingo-oophorectomy
#19
Heather Miller, Laura S Pipkin, Celestine Tung, Tracilyn R Hall, Ramya P Masand, Matthew L Anderson
STUDY OBJECTIVE: Assess the potential role of peritoneal and omental biopsies in women undergoing risk-reducing salpingo-oopherectomy (RRSO) for prophylactic management of hereditary breast/ovarian cancer syndromes (HBOC). DESIGN: Retrospective observational cohort DESIGN: Classification: II.1 SETTING: Academic gynecology practice PATIENTS: All women who underwent RRSO for a high risk BRCA1/2 mutation or deletion at a single institution between January, 2003 and June, 2016...
March 8, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28284216/does-serum-ca125-have-clinical-value-for-follow-up-monitoring-of-postoperative-patients-with-epithelial-ovarian-cancer-results-of-a-12-year-study
#20
Na Guo, Zhilan Peng
BACKGROUND: The detection of CA125 has been used in the follow up of ovarian cancer. At present, some scholars believe that serum CA125 has no clinical value for the follow-up monitoring the recurrence for postoperative patients with epithelial ovarian cancer, but in our clinical follow-up found that when the serum CA125 value is <35 U/ml, postoperative patients of epithelial ovarian carcinoma had already showed recurrent lesions in some ecological and imaging examinations or in laparotomy exploration and biopsy, and we given the patients timely treatment, the prognosis were improved...
March 11, 2017: Journal of Ovarian Research
keyword
keyword
103066
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"